Edward Victor Ross
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Edward Victor Ross has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Jill S. Waibel
Miami Dermatology & Laser Institute Miami Florida USA
3 shared publications Omar A. Ibrahimi
Connecticut Skin Institute Stamford Connecticut USA
3 shared publicationsYacov Domankevitz
Candela Corporation Wayland California
3 shared publications- Arielle Kauvar
New York Laser & Skin Care New York New York USA
2 shared publications - Bianca Y. Kang
Department of Dermatology Mayo Clinic Scottsdale Arizona USA
2 shared publications Briana Wischnack
Division of Dermatology Scripps Clinic San Diego California USA
2 shared publications
Latest Publications
- 11 June 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (6) , 477-489
Consensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face
Objectives: To achieve consensus among expert laser surgeons on standards for the prevention and management of adverse events from fully ablative laser resurfacing of the face.Materials and Methods: Delphi study with two rounds of ratings and revisions until consensus was achieved. The draft set of statements was developed by a steering committee based on expert clinical experience. This was followed by two rounds of rating and revisions completed by an expert panel, then a virtual consensus meeting. In both rounds, respondents rated the draft statements on a 9‐point Likert scale (1 = strongly disagree; 9 = strongly agree) and optionally provided comments. The consensus meeting was supplemented by the results of a systematic review of the literature (from 2000 to 2023).Results: Two rounds of Delphi survey were completed by 34 participants across four countries. Represented specialties were dermatology, facial plastic surgery, plastic surgery, and oculoplastic surgery. The initial 105 statements from round 1 expanded to 112 in round 2, with 96 statements achieving consensus. These included possible adverse events (11 statements); absolute and relative contraindications to treatment (5 statements); preoperative care and antimicrobial prophylaxis precautions (16 statements); intraoperative precautions (17 statements); postoperative care (21 statements); monitoring for and management of infection (16 statements); management of pigmentation changes (6 statements); and management of scarring and incipient scarring (4 statements).Conclusion: An international consensus statement was developed for the prevention and management of complications associated with fully ablative laser resurfacing of the face. While expert practices vary, key factors for optimizing outcomes include careful patient selection, counseling, and meticulous pre‐ and postoperative care. Further research will improve our understanding of this treatment technique.
- 11 June 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (6) , 477-489
Consensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face
Objectives: To achieve consensus among expert laser surgeons on standards for the prevention and management of adverse events from fully ablative laser resurfacing of the face.Materials and Methods: Delphi study with two rounds of ratings and revisions until consensus was achieved. The draft set of statements was developed by a steering committee based on expert clinical experience. This was followed by two rounds of rating and revisions completed by an expert panel, then a virtual consensus meeting. In both rounds, respondents rated the draft statements on a 9‐point Likert scale (1 = strongly disagree; 9 = strongly agree) and optionally provided comments. The consensus meeting was supplemented by the results of a systematic review of the literature (from 2000 to 2023).Results: Two rounds of Delphi survey were completed by 34 participants across four countries. Represented specialties were dermatology, facial plastic surgery, plastic surgery, and oculoplastic surgery. The initial 105 statements from round 1 expanded to 112 in round 2, with 96 statements achieving consensus. These included possible adverse events (11 statements); absolute and relative contraindications to treatment (5 statements); preoperative care and antimicrobial prophylaxis precautions (16 statements); intraoperative precautions (17 statements); postoperative care (21 statements); monitoring for and management of infection (16 statements); management of pigmentation changes (6 statements); and management of scarring and incipient scarring (4 statements).Conclusion: An international consensus statement was developed for the prevention and management of complications associated with fully ablative laser resurfacing of the face. While expert practices vary, key factors for optimizing outcomes include careful patient selection, counseling, and meticulous pre‐ and postoperative care. Further research will improve our understanding of this treatment technique.
- Open Access
- 21 October 2024
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (1) , 15-26
Expert Consensus on Clinical Recommendations for Fractional Ablative CO2 Laser, in Facial Skin Rejuvenation Treatment
Background: For three decades, fractional ablative CO2 lasers have been used for skin rejuvenation. With breakthroughs in laser technology and expanding popularity, new recommendations and suggestions arise on a regular basis.Objective: To develop up‐to‐date clinical recommendations on safety measures, therapeutic framework, and techniques to improve treatment outcomes.Methods: Using Google Forms, a questionnaire with 188 questions was given to a varied sample of 21 dermatologists and plastic surgeons from various countries and practice contexts. A second questionnaire with 11 items was created to resolve any gaps or discrepancies.Results: Active face infections are considered a treatment contraindication by 95% of panelists. Burns, recent sun exposure, and pregnancy or breastfeeding were also considered contraindications (according to 67% of panelists). Over 90% employ bacterial and viral prophylaxis, however the majority (67%) do not prescribe antifungal prophylaxis. The most often stated anesthetic treatments by panelists are topical anesthetic cream, nerve blocks, and oral analgesics (according to 95%, 81%, and 62% of panelists respectively). Over 90% of panel members suggested treatment setting alterations for individuals with Fitzpatrick skin types III–IV. Following reepithelization, which happens between 8 and 42 days after the treatment, the majority (76%) of panelists advocate continuing standard skin care routines including active ingredients. Eighty‐one percent of panelists recommend using supplementary treatment to maximize results. Supplementary treatment recommendations included use of neuromodulators (76% of panelists), Intense Pulsed Light Therapy treatments pre and postprocedure (61% of panelists), and injection‐based therapies such as (Hyaluronic Acid fillers, and biostimulatory fillers) (recommended by 48% of panelists). 60% of panelists perform FACL to improve skin laxity treatment in nonfacial areas and adjust their settings accordingly.Limitations: Our results reflect only a modest panel size; with a focus on a specific device. Although experienced, the small number of panelists, recommendations, and personal adverse reactions encounters for resurfacing indication, might be biased.Conclusion: Fractional CO2 laser is a popular and effective skin rejuvenation treatment with minimal downtime and side effects. This study presents new therapy recommendations to resolve treatment uncertainty and provide complete care suggestions for best results.
- 21 October 2024
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (1) , 15-26
Open AccessExpert Consensus on Clinical Recommendations for Fractional Ablative CO2 Laser, in Facial Skin Rejuvenation Treatment
Background: For three decades, fractional ablative CO2 lasers have been used for skin rejuvenation. With breakthroughs in laser technology and expanding popularity, new recommendations and suggestions arise on a regular basis.Objective: To develop up‐to‐date clinical recommendations on safety measures, therapeutic framework, and techniques to improve treatment outcomes.Methods: Using Google Forms, a questionnaire with 188 questions was given to a varied sample of 21 dermatologists and plastic surgeons from various countries and practice contexts. A second questionnaire with 11 items was created to resolve any gaps or discrepancies.Results: Active face infections are considered a treatment contraindication by 95% of panelists. Burns, recent sun exposure, and pregnancy or breastfeeding were also considered contraindications (according to 67% of panelists). Over 90% employ bacterial and viral prophylaxis, however the majority (67%) do not prescribe antifungal prophylaxis. The most often stated anesthetic treatments by panelists are topical anesthetic cream, nerve blocks, and oral analgesics (according to 95%, 81%, and 62% of panelists respectively). Over 90% of panel members suggested treatment setting alterations for individuals with Fitzpatrick skin types III–IV. Following reepithelization, which happens between 8 and 42 days after the treatment, the majority (76%) of panelists advocate continuing standard skin care routines including active ingredients. Eighty‐one percent of panelists recommend using supplementary treatment to maximize results. Supplementary treatment recommendations included use of neuromodulators (76% of panelists), Intense Pulsed Light Therapy treatments pre and postprocedure (61% of panelists), and injection‐based therapies such as (Hyaluronic Acid fillers, and biostimulatory fillers) (recommended by 48% of panelists). 60% of panelists perform FACL to improve skin laxity treatment in nonfacial areas and adjust their settings accordingly.Limitations: Our results reflect only a modest panel size; with a focus on a specific device. Although experienced, the small number of panelists, recommendations, and personal adverse reactions encounters for resurfacing indication, might be biased.Conclusion: Fractional CO2 laser is a popular and effective skin rejuvenation treatment with minimal downtime and side effects. This study presents new therapy recommendations to resolve treatment uncertainty and provide complete care suggestions for best results.
- 1 October 2022
- Published by SanovaWorks in Journal Of Drugs In Dermatology
- Vol. 21 (11) , 1221-1227
Subject Satisfaction of Wrinkle Reduction Following Treatment with Fractional Radiofrequency: A Prospective Study
Background: Fractional radiofrequency (FRF) technology reduces skin laxity and treats aging-related skin disorders such as wrinkles. The objective of this study was to evaluate participant satisfaction of FRF for the treatment of facial wrinkles. Methods: A total of 25 male and female patients (average age 60.5 years) were enrolled in this prospective, single center study. Patients received 3 FRF treatments at 3- to 5-week intervals on both sides of the face, using 80-pin (up to 124 millijoule/pin) or the 160-pin tip (up to 62 millijoule/pin) applicator. Follow-up visits were conducted at 6 and 12 weeks after the last treatment. Participant satisfaction was evaluated by individual self-assessment of wrinkle reduction and a patient satisfaction questionnaire. Pain, tolerability, and safety were monitored throughout. Results: The individual satisfaction was high with participants giving an average satisfaction score of 2.8 (satisfied) out of 4. Pain was rated mild with an average of 4.0 on a 10-point Visual Analog Scale (VAS). Tolerability was rated 3.3 out of 4.0, correlating to very tolerable. Ninety percent (90%) of subjects reported a mild or moderate improvement in their treatment area at 12-week follow-up. Conclusion: This study demonstrates that under the FRF pre-sets used, patients are satisfied with results of FRF modality for improvement of their wrinkles. No unanticipated side effects were observed. Treatment was tolerable, and individuals had high levels of satisfaction and tolerability with the results at last follow-up. J Drugs Dermatol. 2022;21(11):1221-1227. doi:10.36849/JDD.6986Wrinkle Reduction, Fractional Radiofrequency
- 1 October 2022
- Published by SanovaWorks in Journal Of Drugs In Dermatology
- Vol. 21 (11) , 1221-1227
Subject Satisfaction of Wrinkle Reduction Following Treatment with Fractional Radiofrequency: A Prospective Study
Background: Fractional radiofrequency (FRF) technology reduces skin laxity and treats aging-related skin disorders such as wrinkles. The objective of this study was to evaluate participant satisfaction of FRF for the treatment of facial wrinkles. Methods: A total of 25 male and female patients (average age 60.5 years) were enrolled in this prospective, single center study. Patients received 3 FRF treatments at 3- to 5-week intervals on both sides of the face, using 80-pin (up to 124 millijoule/pin) or the 160-pin tip (up to 62 millijoule/pin) applicator. Follow-up visits were conducted at 6 and 12 weeks after the last treatment. Participant satisfaction was evaluated by individual self-assessment of wrinkle reduction and a patient satisfaction questionnaire. Pain, tolerability, and safety were monitored throughout. Results: The individual satisfaction was high with participants giving an average satisfaction score of 2.8 (satisfied) out of 4. Pain was rated mild with an average of 4.0 on a 10-point Visual Analog Scale (VAS). Tolerability was rated 3.3 out of 4.0, correlating to very tolerable. Ninety percent (90%) of subjects reported a mild or moderate improvement in their treatment area at 12-week follow-up. Conclusion: This study demonstrates that under the FRF pre-sets used, patients are satisfied with results of FRF modality for improvement of their wrinkles. No unanticipated side effects were observed. Treatment was tolerable, and individuals had high levels of satisfaction and tolerability with the results at last follow-up. J Drugs Dermatol. 2022;21(11):1221-1227. doi:10.36849/JDD.6986Wrinkle Reduction, Fractional Radiofrequency
- Open Access
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (10) , 1193-1201
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Importance: Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.Objective: To develop recommendations for the safe and effective use of LADD.Evidence Review: A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.Findings: Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.Conclusions and Relevance: This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (10) , 1193-1201
Open AccessEvidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Importance: Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.Objective: To develop recommendations for the safe and effective use of LADD.Evidence Review: A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.Findings: Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.Conclusions and Relevance: This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
- Open Access
- 14 January 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (2) , 195-200
1,550 nm Erbium-Doped and 1,927 nm Thulium Nonablative Fractional Laser System: Best Practices and Treatment Setting Recommendations
BACKGROUND: The Fraxel Dual laser system (Solta Medical, Inc., Bothell, WA) contains a 1,550 and 1,927 nm wavelength single handpiece with different indications for each wavelength. OBJECTIVE: To discuss treatment setting recommendations and best practices for select on-label and investigational applications of the 1,550 and 1,927 nm dual laser system. MATERIALS AND METHODS: Eight board-certified dermatologists with 10 or more years of experience with the 1,550 and 1,927 nm laser system completed an online survey about their clinical experience with the system and then participated in a roundtable to share clinical perspectives and best practices for using the laser system. RESULTS: For all Fitzpatrick skin types, treatment recommendations were described for selected approved indications for the 1,550 and 1,927 nm laser system, including both lasers in combination. Treatment recommendations were also reached for investigational applications with the 1,550 nm laser and 1,927 nm laser. Best practices for using the lasers during the treatment session to achieve optimal outcomes and decrease the post-treatment recovery time were compiled. CONCLUSION: The 1,550 and 1,927 nm dual laser system is effective for a wide range of aesthetic and therapeutic applications, on and off the face and across all Fitzpatrick skin types.
- 14 January 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (2) , 195-200
Open Access1,550 nm Erbium-Doped and 1,927 nm Thulium Nonablative Fractional Laser System: Best Practices and Treatment Setting Recommendations
BACKGROUND: The Fraxel Dual laser system (Solta Medical, Inc., Bothell, WA) contains a 1,550 and 1,927 nm wavelength single handpiece with different indications for each wavelength. OBJECTIVE: To discuss treatment setting recommendations and best practices for select on-label and investigational applications of the 1,550 and 1,927 nm dual laser system. MATERIALS AND METHODS: Eight board-certified dermatologists with 10 or more years of experience with the 1,550 and 1,927 nm laser system completed an online survey about their clinical experience with the system and then participated in a roundtable to share clinical perspectives and best practices for using the laser system. RESULTS: For all Fitzpatrick skin types, treatment recommendations were described for selected approved indications for the 1,550 and 1,927 nm laser system, including both lasers in combination. Treatment recommendations were also reached for investigational applications with the 1,550 nm laser and 1,927 nm laser. Best practices for using the lasers during the treatment session to achieve optimal outcomes and decrease the post-treatment recovery time were compiled. CONCLUSION: The 1,550 and 1,927 nm dual laser system is effective for a wide range of aesthetic and therapeutic applications, on and off the face and across all Fitzpatrick skin types.
- 23 December 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 54 (1) , 152-156
“Photon recycling” can enhance cutaneous response to lasers: A pilot human study
Background: Depending on wavelength and pigmentation, human skin can reflect up to 70% of incident laser light.Aims: We tested the hypothesis that returning (“recycling”) this diffusely reflected light to the site of laser exposure would increase cutaneous response.Materials and Methods: Thirteen adult volunteers with Fitzpatrick skin types I–IV participated in this IRB‐approved study. Matched contralateral test sites on the volar forearms were exposed to a pulsed dye laser operated at 585 nm, 450 microseconds pulse duration in a uniform 5 mm circular exposure spot without skin cooling. On one arm, the laser handpiece was fitted with an aluminized hemispherical mirror with a reflectance of 67%. The minimum fluence causing skin purpura, and the purpura lesion diameter were measured.Results: The mean purpura threshold fluence with the reflector was 3.1 J/cm2 (0.5 SD), and 3.7 J/cm2 without the reflector (0.36 SD) (p < 0.001). The mean laser‐induced purpura lesion diameter was approximately 5.3 mm with the reflector and 5.0 mm without the reflector.Conclusion: Consistent with a theoretical model and in vitro measurements, this human study confirms that “recycling” reflected laser light can increase skin response. Potentially, the therapeutic response can also be improved with “photon recycling.”
- 23 December 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 54 (1) , 152-156
“Photon recycling” can enhance cutaneous response to lasers: A pilot human study
Background: Depending on wavelength and pigmentation, human skin can reflect up to 70% of incident laser light.Aims: We tested the hypothesis that returning (“recycling”) this diffusely reflected light to the site of laser exposure would increase cutaneous response.Materials and Methods: Thirteen adult volunteers with Fitzpatrick skin types I–IV participated in this IRB‐approved study. Matched contralateral test sites on the volar forearms were exposed to a pulsed dye laser operated at 585 nm, 450 microseconds pulse duration in a uniform 5 mm circular exposure spot without skin cooling. On one arm, the laser handpiece was fitted with an aluminized hemispherical mirror with a reflectance of 67%. The minimum fluence causing skin purpura, and the purpura lesion diameter were measured.Results: The mean purpura threshold fluence with the reflector was 3.1 J/cm2 (0.5 SD), and 3.7 J/cm2 without the reflector (0.36 SD) (p < 0.001). The mean laser‐induced purpura lesion diameter was approximately 5.3 mm with the reflector and 5.0 mm without the reflector.Conclusion: Consistent with a theoretical model and in vitro measurements, this human study confirms that “recycling” reflected laser light can increase skin response. Potentially, the therapeutic response can also be improved with “photon recycling.”
- 22 September 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (1) , 109-113
Study of a 532/1064 Fractional Picosecond Laser for Facial Rejuvenation
BACKGROUND AND OBJECTIVES: Picosecond (ps) fractional lasers create small wounds, presumably by laser-induced optical breakdown. We studied a ps fractional laser in the treatment of wrinkles and mottled pigment. MATERIALS AND METHODS: This was a single center, prospective, open-label clinical trial. Patients with at least 2 facial areas, with visible wrinkles and dyschromia, were enrolled in the study and received 3 treatments at monthly intervals and appeared at 3 follow-up visits at 1, 3, and 6 months after treatment. The laser is an 800 ps fractional system with nominal 10 mm macrospot diameter. Both 532 nm and 1,064 nm wavelengths were applied in each subject. Wrinkle and pigmentation clearance were assessed by 2 blinded investigators using a 5-point clearance scale. Skin improvement was assessed by investigators using the 5-point Global Aesthetic Improvement (GAI) Scale based on before/after photographs for the following categories: (1) fine lines/wrinkles and (2) pigmentation. RESULTS: A total of 18 healthy subjects at a single site were enrolled. At least moderate pigmentation and fine line/wrinkles improvement were observed in 93% and 79% of patients at 1 month after the last treatment according to GAI, respectively. Pigment clearance approached a mean of approximately 40%. CONCLUSION: A ps 1,064/532 fractional laser achieves reduction in fine lines and pigment.
- 22 September 2021
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (1) , 109-113
Study of a 532/1064 Fractional Picosecond Laser for Facial Rejuvenation
BACKGROUND AND OBJECTIVES: Picosecond (ps) fractional lasers create small wounds, presumably by laser-induced optical breakdown. We studied a ps fractional laser in the treatment of wrinkles and mottled pigment. MATERIALS AND METHODS: This was a single center, prospective, open-label clinical trial. Patients with at least 2 facial areas, with visible wrinkles and dyschromia, were enrolled in the study and received 3 treatments at monthly intervals and appeared at 3 follow-up visits at 1, 3, and 6 months after treatment. The laser is an 800 ps fractional system with nominal 10 mm macrospot diameter. Both 532 nm and 1,064 nm wavelengths were applied in each subject. Wrinkle and pigmentation clearance were assessed by 2 blinded investigators using a 5-point clearance scale. Skin improvement was assessed by investigators using the 5-point Global Aesthetic Improvement (GAI) Scale based on before/after photographs for the following categories: (1) fine lines/wrinkles and (2) pigmentation. RESULTS: A total of 18 healthy subjects at a single site were enrolled. At least moderate pigmentation and fine line/wrinkles improvement were observed in 93% and 79% of patients at 1 month after the last treatment according to GAI, respectively. Pigment clearance approached a mean of approximately 40%. CONCLUSION: A ps 1,064/532 fractional laser achieves reduction in fine lines and pigment.
- Open Access
- 25 August 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 54 (1) , 189-192
Airborne particulate concentration during non‐thermal nano‐pulse stimulation wart clearance is negligible compared to thermal modalities
Objectives: As clinicians continue to implement safety protocols amid the global pandemic, considerations to mitigate potential viral transmission of airborne particulates (plume) generated from certain dermatologic procedures are of growing interest. This study intended to measure the change in airborne particulate matter using a non‐thermal energy modality called nano‐pulse stimulation (NPS) and compare levels of concentration to common thermal modalities (CO2 laser and electrocautery). NPS is a new non‐thermal modality that applies nanosecond pulses of electrical energy to induce regulated cell death in cellular structures while sparing the surrounding acellular structure of the dermis.Materials and Methods: The study used a Condensation Particle Counter during four types of dermatologic procedures: (1) using non‐thermal NPS for the clearance of cutaneous, nongenital warts; (2) an electrocautery treatment of warts; (3) a CO2 laser for facial resurfacing; and (4) an electrocautery procedure for a facelift. Four subjects and a total of 11 warts were treated with NPS while a particle counter was used to detect the average particles per cubic centimeter once per second. The same particle counter was used, for comparison, during a wart removal procedure using electrocautery for comparison, and for control, during a skin resurfacing procedure with a CO2 laser and a facelift in which electrocautery was used.Results: Only one of the 11 NPS wart procedures generated any detectable change in the particulate concentration and that change was negligible in comparison to the increase in particulate concentration measured during the CO2 laser resurfacing and the electrocautery use during a facelift procedure.Conclusions: Procedures using non‐thermal NPS technology do not generate significant plume when applied to eliminate warts, suggesting it is unlikely that this new energy modality would release viral DNA into the air.
- 25 August 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 54 (1) , 189-192
Open AccessAirborne particulate concentration during non‐thermal nano‐pulse stimulation wart clearance is negligible compared to thermal modalities
Objectives: As clinicians continue to implement safety protocols amid the global pandemic, considerations to mitigate potential viral transmission of airborne particulates (plume) generated from certain dermatologic procedures are of growing interest. This study intended to measure the change in airborne particulate matter using a non‐thermal energy modality called nano‐pulse stimulation (NPS) and compare levels of concentration to common thermal modalities (CO2 laser and electrocautery). NPS is a new non‐thermal modality that applies nanosecond pulses of electrical energy to induce regulated cell death in cellular structures while sparing the surrounding acellular structure of the dermis.Materials and Methods: The study used a Condensation Particle Counter during four types of dermatologic procedures: (1) using non‐thermal NPS for the clearance of cutaneous, nongenital warts; (2) an electrocautery treatment of warts; (3) a CO2 laser for facial resurfacing; and (4) an electrocautery procedure for a facelift. Four subjects and a total of 11 warts were treated with NPS while a particle counter was used to detect the average particles per cubic centimeter once per second. The same particle counter was used, for comparison, during a wart removal procedure using electrocautery for comparison, and for control, during a skin resurfacing procedure with a CO2 laser and a facelift in which electrocautery was used.Results: Only one of the 11 NPS wart procedures generated any detectable change in the particulate concentration and that change was negligible in comparison to the increase in particulate concentration measured during the CO2 laser resurfacing and the electrocautery use during a facelift procedure.Conclusions: Procedures using non‐thermal NPS technology do not generate significant plume when applied to eliminate warts, suggesting it is unlikely that this new energy modality would release viral DNA into the air.
- Open Access
- 19 May 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 53 (10) , 1301-1306
Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
Background and Objectives: This study describes the effects of nano‐pulse stimulation (NPS) technology on the common verruca with the objectives of demonstrating efficacy and safety. NPS technology applies nanosecond pulses of non‐thermal electrical energy to induce highly localized regulated cell death in the cellular structures of the targeted zone with negligible effects on surrounding non‐cellular structures. Previous clinical studies applying NPS to common, benign skin lesions have demonstrated safety and efficacy in clearing seborrheic keratoses and sebaceous hyperplasia.Study Design/Materials and Methods: Sixty‐two subjects were enrolled at a total of five sites. One hundred and ninety‐five study verrucae up to 10 mm wide were treated with NPS delivered by a console‐based handheld applicator (CellFX® System; Pulse Biosciences) and follow‐ups occurred every 30 days with the option to retreat at 30, 60, and 90 days. There were 62 untreated controls and 46% of the treated verrucae were recalcitrant.Results: Overall, 75.3% (70/93) of the common verrucae, 72.7% (8/11) of the flat verrucae, and 43.8% (14/32) of the plantar verrucae treated with NPS were completely clear by 60 days following the last treatment and did not recur within the 120‐day observation period. The majority (54%) of verrucae cleared with a single NPS procedure. The most common treatment site reactions were erythema (50.5%) and eschar formation (23.4%) on Day 30 and on Day 120 mild erythema was present in 14% of the cases and hyperpigmentation in 18.5%. No serious adverse events were reported. A particle counter was used during 11 NPS procedures on verrucae and no significant plume generation was detected during these procedures.Conclusions: NPS is a safe and effective procedure for removing non‐genital, cutaneous verrucae. Lasers Surg. Med. © 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
- 19 May 2021
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 53 (10) , 1301-1306
Open AccessSafety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
Background and Objectives: This study describes the effects of nano‐pulse stimulation (NPS) technology on the common verruca with the objectives of demonstrating efficacy and safety. NPS technology applies nanosecond pulses of non‐thermal electrical energy to induce highly localized regulated cell death in the cellular structures of the targeted zone with negligible effects on surrounding non‐cellular structures. Previous clinical studies applying NPS to common, benign skin lesions have demonstrated safety and efficacy in clearing seborrheic keratoses and sebaceous hyperplasia.Study Design/Materials and Methods: Sixty‐two subjects were enrolled at a total of five sites. One hundred and ninety‐five study verrucae up to 10 mm wide were treated with NPS delivered by a console‐based handheld applicator (CellFX® System; Pulse Biosciences) and follow‐ups occurred every 30 days with the option to retreat at 30, 60, and 90 days. There were 62 untreated controls and 46% of the treated verrucae were recalcitrant.Results: Overall, 75.3% (70/93) of the common verrucae, 72.7% (8/11) of the flat verrucae, and 43.8% (14/32) of the plantar verrucae treated with NPS were completely clear by 60 days following the last treatment and did not recur within the 120‐day observation period. The majority (54%) of verrucae cleared with a single NPS procedure. The most common treatment site reactions were erythema (50.5%) and eschar formation (23.4%) on Day 30 and on Day 120 mild erythema was present in 14% of the cases and hyperpigmentation in 18.5%. No serious adverse events were reported. A particle counter was used during 11 NPS procedures on verrucae and no significant plume generation was detected during these procedures.Conclusions: NPS is a safe and effective procedure for removing non‐genital, cutaneous verrucae. Lasers Surg. Med. © 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.